Cargando…

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men

The safety and immunogenicity of a protein-based tetravalent vaccine SCTV01E that contains spike protein ectodomain (S-ECD) of Alpha, Beta, Delta and Omicron BA.1 are assessed and compared with bivalent protein vaccine SCTV01C (Alpha and Beta variants) and monovalent mRNA vaccine (NCT05323461). The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hannawi, Suad, Saifeldin, Linda, Abuquta, Alaa, Alamadi, Ahmad, Mahmoud, Sally A., Hassan, Aala, Xu, Shuping, Li, Jian, Liu, Dongfang, Baidoo, Adam Abdul Hakeem, Ibrahim, Dima, Alhaj, Mojtaba, Chen, Yuanxin, Zhou, Qiang, Xie, Liangzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329711/ https://www.ncbi.nlm.nih.gov/pubmed/37422518 http://dx.doi.org/10.1038/s41467-023-39766-x

Ejemplares similares

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial
por: Hannawi, Suad, et al.
Publicado: (2022)

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial
por: Hannawi, Suad, et al.
Publicado: (2022)

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial
por: Hannawi, Suad, et al.
Publicado: (2023)

Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study
por: Hannawi, Suad, et al.
Publicado: (2023)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
por: Tan, Ngoc H., et al.
Publicado: (2022)

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
por: Dayan, Gustavo H, et al.
Publicado: (2014)

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children
por: Watanaveeradej, Veerachai, et al.
Publicado: (2016)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Effectiveness of Bivalent Boosters against Severe Omicron Infection
por: Lin, Dan-Yu, et al.
Publicado: (2023)

An Assessment of the Bivalent Vaccine as a Second Booster for COVID-19
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Axillary lymphadenopathy following bivalent COVID-19 booster vaccination
por: Lane, Elizabeth G., et al.
Publicado: (2023)

Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster
por: Jabagi, Marie-Joelle, et al.
Publicado: (2023)

Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
por: El Helou, Guy, et al.
Publicado: (2020)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

Safety, Tolerability, and Immunogenicity of COVID-19 Bivalent Vaccination
por: Saxena, Divyasha, et al.
Publicado: (2023)

A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis
por: Huth, Luca, et al.
Publicado: (2023)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Characterizing healthcare worker attitudes toward the bivalent COVID-19 booster
por: Willebrand, Kathryn, et al.
Publicado: (2023)

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
por: Chalkias, Spyros, et al.
Publicado: (2022)

Comment on: Variables associated with subclinical atherosclerosis among rheumatoid arthritis patients of Gulf Cooperative Council countries’
por: Hannawi, Suad
Publicado: (2020)

Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice
por: Fahimi, Hossein, et al.
Publicado: (2018)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
por: Vigne, Claire, et al.
Publicado: (2017)

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
por: LeFevre, Inge, et al.
Publicado: (2023)

Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth
por: Moyo, Nathifa, et al.
Publicado: (2020)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
por: Alcendor, Donald J., et al.
Publicado: (2023)

2334. The effectiveness of bivalent COVID-19 booster among patients with hematologic malignancies
por: Aleissa, Muneerah M, et al.
Publicado: (2023)

Cardiovascular Risk in Rheumatoid Arthritis: Literature Review
por: Hannawi, Suad MA, et al.
Publicado: (2021)

Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial
por: Wang, Guiqiang, et al.
Publicado: (2022)

Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9–16 Years in Brazil
por: Dayan, Gustavo H., et al.
Publicado: (2013)

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults
por: Kirstein, Judith, et al.
Publicado: (2018)

Birthweight predicts adult cardiovascular disorders: Population based cross sectional survey
por: Salmi, Issa, et al.
Publicado: (2020)

Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
por: Lasrado, Ninaad, et al.
Publicado: (2023)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7c3rktl6r3fqgkkh8c4l5r7g91